Related Experiment Video

Updated: May 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Specific features of hypolipidemic therapy in patients with abdominal ischemic disease]

O Sh Oĭnotkinova

    Terapevticheskii Arkhiv
    |September 22, 2012
    PubMed

    Insights

    Combined therapy with Ursofalk and low-dose statins effectively treats abdominal ischemic disease (AID) and fatty liver in high-risk patients. This approach improves symptoms and lipid profiles without adverse effects.

    Area of Science:

    • Cardiology
    • Gastroenterology
    • Pharmacology

    Background:

    • Atherosclerotic lesions of the abdominal aorta (AA) and its unpaired visceral branches (UVB) can lead to abdominal ischemic disease (AID) and hepatic ischemic steatosis.
    • High-risk patients with AID and associated dyslipidemia often develop fatty liver infiltration, a precursor to steatohepatitis.

    Purpose of the Study:

    • To assess the efficacy and safety of combined Ursofalk and low-dose statin therapy.
    • To evaluate the impact on clinical outcomes and blood lipid profiles in patients with AID and hepatic steatosis.

    Main Methods:

    • 139 patients with AID and ischemic hepatopathy were treated with Ursofalk (10-15 mg/kg/day) and atorvastatin (10-20 mg/day).
    • Diagnosis of AID was confirmed using color duplex scanning, CT angiography, and X-ray contrast aortography.

    Main Results:

    • Combined therapy significantly reduced abdominal pain and improved intestinal dysfunction.
    • Positive changes were observed in blood lipid composition parameters.
    • No significant weight changes or adverse reactions were reported.

    Conclusions:

    • Co-administration of Ursofalk and statins is a reasonable hypolipidemic strategy.
    • This combination therapy is beneficial for patients with AID, dyslipidemia, and fatty liver infiltration.
    • The treatment addresses a condition that is a pre-stage of steatohepatitis.
    Abstract

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Cholesterol: Significance and Regulation01:29

    Cholesterol: Significance and Regulation

    Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
    Considering cholesterol and...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Cholecystitis01:20

    Cholecystitis

    Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...